New drug aims to build muscle in rare muscular dystrophy
Disease control
Not yet recruiting
This Phase 2 study tests a drug called apitegromab in 60 adults with facioscapulohumeral muscular dystrophy (FSHD), a genetic condition that causes muscle weakness. Participants will receive either the drug or a placebo every 4 weeks for a year. The main goal is to see if the dru…
Phase: PHASE2 • Sponsor: Scholar Rock, Inc. • Aim: Disease control
Last updated Jun 27, 2026 09:09 UTC